Background and objectives: Anabolic androgenic steroids (AAS) are mainly used for aesthetic and performance-enhancing reasons. Their use is a growing public health problem and concern for society because of their adverse effects. The primary aim of this study was to identify psychiatric and personality disorders and to measure anxiety and depression in AAS users. Materials and Methods: Fifty-six males who actively contacted the Anti-Doping Hot-Line and wished to stop using AAS were included. Structured Clinical Interviews Diagnosis-I and -II were used to diagnose psychiatric and personality disorders. The Brief Scale for Anxiety and Montgomery Asberg Depression Rating Scale (subscales from the Comprehensive Psychopathological Rating Scale) were used to measure changes in anxiety and depression. Structured Clinical Interviews Diagnosis-I and -II were performed at one time point. Anxiety and depression were measured at inclusion and after six months. Urine samples were collected for an analysis of AAS and drugs of abuse. Results: All participants reported some adverse effects that they associated with AAS use. In total, 56% and 52% of the cohort fulfilled the criteria for Structured Clinical Interviews Diagnosis-I and -II diagnoses, respectively. A significantly increased risk of reporting aggressive feelings/behaviors (Odds Ratio (OR) = 4.9; Confidence Interval (CI) 0.99–25, p = 0.04), suicidal thoughts/attempts (OR = 4.6, CI 95; 0.99–21, p = 0.04) and criminality (OR = 6.5, CI 1–39, p = 0.03) was found among individuals with AAS use fulfilling the criteria for personality disorders compared with those without such AAS use. The Brief Scale for Anxiety score decreased from the median of 15 at inclusion to 10 at the follow-up visit six months later (p = 0.01, n = 19). Conclusions: Our findings indicate that among individuals with AAS use, those with a personality disorder report more aggressive behaviors, suicidal thoughts/suicidal attempts, and criminality than those without a personality disorder.

We find no correlation between duration of the first stage of labor and umbilical artery pH or base excess. We do find a correlation between duration of the second stage of labor and the umbilical artery pH and base excess. However, a prolongation of the second stage with as much as three hours would give an expected lowering of the umbilical artery pH with only 0.05 and of base excess with 2.1 mmol/l for vaginal nulliparas and correspondingly with 0.09 and 3.9 mmol/l in women with previous vaginal births. This effect on pH and base excess is so small that it is hardly clinically relevant and we do not find any support for the belief that a long labor -- in the absence of other risk factors -- is to the disadvantage of the fetus.

We find no correlation between duration of the first stage of labor and umbilical artery pH or base excess. We do find a correlation between duration of the second stage of labor and the umbilical artery pH and base excess. However, a prolongation of the second stage with as much as three hours would give an expected lowering of the umbilical artery pH with only 0.05 and of base excess with 2.1 mmol/l for vaginal nulliparas and correspondingly with 0.09 and 3.9 mmol/l in women with previous vaginal births. This effect on pH and base excess is so small that it is hardly clinically relevant and we do not find any support for the belief that a long labor -- in the absence of other risk factors -- is to the disadvantage of the fetus.